Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Bristol Myers Squibb Co
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Pharmaceutical Preparations
No intraday reading yet this session.
Sources
sec edgar · verbatim disclosureEach tie, with the sentence that disclosed it. Open a row for the wording and the filing it came from.
“In September 2019, Legacy Q32 entered into a license agreement, as amended in August 2021 and July 2022 (the "BMS License Agreement") with Bristol-Myers Squibb Company ("BMS"), pursuant to which we obtained sublicensable licenses from BMS to research, develop and commercialize licensed products, including bempikibart, for any and all uses worldwide.”
FILING10-K0001193125-26-099339cik 0001661998disclosed by QTTB
“In the past, we have received a number of significant payments from collaboration agreements and other significant transactions, including $1.9 billion in total consideration received under our arrangement with BMS, development cost reimbursements from BMS, and a $150.0 million upfront payment from Eli Lilly and Company for our collaboration agreement for rezpegaldesleukin.”
FILING10-K0001193125-26-104547cik 0000906709disclosed by NKTR
“BMS received an exclusive worldwide license to develop, manufacture, and commercialize AGEN1777 and its derivatives.”
FILING10-K0001193125-26-108632cik 0001098972disclosed by AGEN
“Pursuant to the BMS Agreement, the financial consideration from Bristol Myers Squibb was comprised of an upfront payment of $50.0 million and estimated research and development service fees, and we were initially entitled to receive contingent payments of up to $25.0 million for additional targets and contingent payments for development, regulatory and sales milestones.”
FILING10-K0001193125-26-107146cik 0001501989disclosed by CTMX
“In connection with our collaboration with BMS, we have received an aggregate of $159.0 million in payments, which have primarily consisted of the initial upfront and amendment payments, development milestone payments, research funding support, and certain opt-in fees.”
FILING10-K0001650664-26-000017cik 0001650664disclosed by EDIT
“We currently have ENHANZE collaborations and licensing agreements with F. Hoffmann-La Roche, Ltd. and Hoffmann-La Roche, Inc. ("Roche"), Takeda Pharmaceuticals International AG and Baxalta US Inc. ("Takeda"), Pfizer Inc. ("Pfizer"), Janssen Biotech, Inc. ("Janssen"), AbbVie, Inc. ("AbbVie"), Eli Lilly and Company ("Lilly"), Bristol Myers Squibb Company ("BMS"), argenx BVBA ("argenx"), ViiV Healthcare (the global specialist HIV Company majority owned by GlaxoSmithKline) ("ViiV"), Chugai Pharmaceutical Co., Ltd. ("Chugai"), Acumen Pharmaceuticals, Inc. ("Acumen"), Merus N.V. ("Merus") and Skye Bioscience, Inc. ("Skye Bioscience").”
FILING10-K0001159036-26-000024cik 0001159036disclosed by HALO
“Under the terms of the Collaboration Agreement, Bristol-Myers Squibb made a non-refundable, upfront cash payment of $100.0 million and purchased 2,160,760 shares of our common stock at a price per share of $23.14, for an aggregate purchase price of $50.0 million.”
FILING10-K0001104659-26-026759cik 0001850119disclosed by IPSC
“In September 2024, we entered into a stock purchase agreement with BMS, or the BMS Purchase Agreement, pursuant to which we agreed to issue and sell, and BMS agreed to purchase, 11,006,163 shares of our common stock, or the BMS Shares, for an aggregate purchase price of $55.0 million pursuant to the terms and conditions thereof.”
FILING10-K0001628280-26-013569cik 0001894562disclosed by PRME
“Pursuant to the Collaboration Agreement with BMS, we are eligible to receive payments for commercial and regulatory milestones and royalties on net sales of Collaboration Products.”
FILING10-K0001559053-26-000008cik 0001559053disclosed by PRTA
“We are party to an exclusive, worldwide collaboration and license agreement with BMS, pursuant to which we and BMS agreed to collaborate in the discovery, research and development of small molecule compounds for biological targets in the oncology, neurology and immunology therapeutic areas.”
FILING10-K0001490978-26-000010cik 0001490978disclosed by SDGR
“The parties agreed that we will manufacture and supply and BMS will exclusively purchase all of BMS's requirements of (a) Products (and placebo) for development in the BMS Territory, subject to the terms of a separate clinical supply agreement and clinical supply quality agreement, to be executed after the BMS Effective Date and (b) finished Products for commercialization in the BMS Territory, subject to the terms of a separate commercial supply agreement and commercial supply quality agreement, to be executed within a certain number of months prior to the first regulatory approval in the BMS Territory.”
FILING10-K0001104659-26-027964cik 0001953926disclosed by ZBIO
“Under the terms of the agreement with BMS, we are sponsoring the trial as a new arm of the STOMP Trial and BMS will supply the trial's clinical drug mezigdomide.”
FILING10-K0001193125-26-049397cik 0001503802disclosed by KPTI
“On February 12, 2024, for total cash consideration paid of $3.0 million, we repurchased the 552,307 shares previously sold to Bristol Myers Squibb Company (BMS).”
FILING10-K0001193125-26-104547cik 0000906709disclosed by NKTR
“In April 2019, we entered into a separate agreement with BMS on terms similar to the terms set forth in the agreement described above, pursuant to which BMS will provide, at no cost to us, nivolumab for use in our Phase 1 clinical trial of RP2 in combination with nivolumab.”
FILING10-K0001628280-26-045886cik 0001737953disclosed by REPL
“We provided GPS and Bristol-Myers Squibb provided nivolumab for this study.”
FILING10-K0001390478-26-000003cik 0001390478disclosed by SLS
“In February 2004, we entered into a license agreement with Bristol-Myers Squibb (BMS) under which we received an exclusive worldwide license under certain patents and patent applications, and other licenses to intellectual property, to develop and commercialize HETLIOZ ® .”
FILING10-K0001628280-26-007460cik 0001347178disclosed by VNDA
“In June 2024, the Group entered into a clinical trial collaboration and supply agreement with Bristol-Myers Squibb Company”
FILING20-F0001778016-26-000002cik 0001778016disclosed by NBP
“License Agreements and Strategic Collaborations Collaboration and Supply Agreement with Bristol-Myers Squibb On January 5, 2022, we and Bristol-Myers Squibb Company ("BMS") entered into a clinical trial collaboration and supply agreement (the "BMS Agreement").”
FILING10-K0001193125-26-134499cik 0001826892disclosed by BCAB
“In December 2014, we entered into a collaboration agreement with Celgene (now BMS) to research, develop and commercialize bispecific antibodies generated through the use of our Azymetric platform.”
FILING10-K0001937653-26-000015cik 0001937653disclosed by ZYME
“For example, in 2018, we and Sanofi entered into a license agreement with Bristol-Myers Squibb, E. R. Squibb & Sons, and Ono Pharmaceutical to obtain a license under certain patents owned and/or exclusively licensed by one or more of these parties that includes the right to develop and sell Libtayo.”
FILING10-K0001804220-25-000011cik 0000872589disclosed by REGN
“31, 2025, the Group had two revenue-generating strategic collaboration agreements in place, one with Bristol-Myers-Squibb ("BMS") and one agreement with ModernaTX, Inc. ("Moderna"), which both are in pre-clinical stage.”
FILING20-F0001193125-26-092529cik 0001809196disclosed by IMTX
“we entered into an agreement with BMS to evaluate the safety and efficacy of INT230-6 with Yervoy ® (ipilimumab), BMS's CTLA-4 immune checkpoint inhibitor, in patients with breast (17%), liver (5%), and advanced sarcoma cancer (78%).”
FILING10-K0001567264-26-000024cik 0001567264disclosed by INTS
“In addition, we are entitled to receive clinical and regulatory milestone payments ranging, depending on the timing and extent of our efforts in the alliance, up to $76 million for each drug developed by Bristol-Myers Squibb under the alliance.”
FILING10-K0001062822-26-000050cik 0001062822disclosed by LXRX
“In February 2022, we announced a worldwide license agreement with BMS for the development and commercialization rights to taldefgrobep alfa (also known as BMS-986089), a novel Phase 3 asset.”
FILING10-K0001935979-26-000020cik 0001935979disclosed by BHVN
Watchlist prices, news filtered to it, and its next report on your desk.
Bristol Myers Squibb Co has 15 disclosed suppliers and 16 disclosed customers. Each one is named in an SEC filing, either Bristol Myers Squibb Co’s own annual report or the counterparty’s, and carries the sentence that discloses it.
BMY (Bristol Myers Squibb Co) has 15 disclosed suppliers and 16 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move, and a bundle sits past the rings until you open it. Extended: satellites hang off single companies, not bundled sectors.
Largest move on the map today: EDIT −4.20%, in the health bundle.